Interní Med. 2005; 7(12): 566-569

Postmenopauzální osteoporóza

MUDr. Tomáš Hála
Ústav zdravotnických studií, Univerzita Pardubice, Pardubice

Osteoporóza je civilizační choroba a představuje velký problém medicínský, ekonomický a sociální. Následkem osteoporózy dochází ke zlomeninám, z nich hlavně zlomeniny obratlů a krčku stehenní kosti vedou k nárůstu morbidity a mortality (3). Velká část pacientů je výrazně postižena a dochází k rozvoji disability, závislosti na pomoci druhých osob a také ke ztrátě sociálních rolí ve společnosti.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hála T. Postmenopauzální osteoporóza. Interní Med. 2005;7(12):566-569.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bayer M, Blahoš J, Broulík P, Doleček R, Donát J, Havelka S, Kasalický P, Kutílek Š, Palička V, Štěpán J, Trnavský K, Vyskočil V, Wilczek H.Doporučené postupy pro diagnostiku a terapii postmenopauzální osteoporózy. Osteol Bull 2003; 8: 8-13.
    2. Black DM, Thompson DE, Bauer DC, et al (FIT Research Group). Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 4118-4124. Go to original source... Go to PubMed...
    3. Cummings SR, Melton J III. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767. Go to original source... Go to PubMed...
    4. Consensus development konference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-650. Go to original source... Go to PubMed...
    5. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud K, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282: 637-645. Go to original source... Go to PubMed...
    6. Harris ST, Watts NB, Genant HK, et al (Vertebral Efficacy with Risedronate Therapy [VERT] Study Group). Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344-1352. Go to original source... Go to PubMed...
    7. Chesnut CH 3 rd, Silverman S, Andriano K, Genant H, at al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000 Sep; 109 (4): 267-276.
    8. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD. Effect of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249. Go to original source... Go to PubMed...
    9. Jalovaara P, Virkkunen H. Quality of life after primary hemiarthroplasty for femoral neck fracture:6-year follow-up of 185 patients. Acta Orthop Scand 1991; 62 (3): 208-217. Go to original source... Go to PubMed...
    10. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285 (3): 320-323. Go to original source... Go to PubMed...
    11. Melton LJ III, Hamer M, Ray NF, et al. Fractures attributable to osteoporosis:report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12 (1): 16-23. Go to original source... Go to PubMed...
    12. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY. The effect of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004; 350: 459-468. Go to original source... Go to PubMed...
    13. MiIler PD, McClung MR, Macovei L, Staklestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendeler DL, Bolognese MA, Mairon N, Cooper C. Monthly oral ibanmdronate theraphy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315-1322. Go to original source... Go to PubMed...
    14. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med. 2001; 344: 1434-1441. Go to original source... Go to PubMed...
    15. NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795. Go to original source... Go to PubMed...
    16. Reginster J, Minne HW, Sorensen OH, et al. (Vertebral Efficacy with Risedronate Therapy [VERT] Study Group). Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000; 11: 83-91. Go to original source... Go to PubMed...
    17. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos, Devogelaer JP, Curiel MD, Sawicky A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ. Strontium Ranelate Reduces the Risk of Nonvertebral Fratures in Postmenopausal Women with Osteoporois: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab. 2005; 90: 2816-2822. Go to original source... Go to PubMed...
    18. Suda T, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 1999; 20: 345-357. Go to original source... Go to PubMed...
    19. Štěpán JJ, Havelka S, Kamberská Z. Epidemiologie der Osteoporose in der Tschechischen Republik. J Minerastoffwechsel 2002; 9: 7-13.
    20. Walker N, Norton R, Vander Hoorn S, et al. Mortality after hip fracture:regional variations in New Zealand. N Z Med J 1999; 112 (1092): 269-271. Go to PubMed...
    21. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.